Ultragenyx Pharmaceutical secured $75 million in a Series B funding round and will use the money to further develop its lead drug candidates, UX001 and UX003. UX001 is being developed as a replacement therapy for hereditary inclusion body myopathy, while UX003 is an experimental enzyme replacement therapy for mucopolysaccharidosis type 7.

Related Summaries